Camelid reporter gene imaging: a generic method for in vivo cell tracking by Lode RY Goethals et al.
Goethals et al. EJNMMI Research 2014, 4:32
http://www.ejnmmires.com/content/4/1/32ORIGINAL RESEARCH Open AccessCamelid reporter gene imaging: a generic
method for in vivo cell tracking
Lode RY Goethals1,2*, Tomas J Bos3, Luc Baeyens4, Frank De Geeter1, Nick Devoogdt1 and Tony Lahoutte1,5Abstract
Background: To combine the sensitivity of bioluminescent imaging (BLI) with the 3D and quantitative properties of
pinhole single-photon emission computed tomography (SPECT)/micro-computed tomography (CT) (phSPECT/micro-CT),
we generated stable cell lines that express a yellow-fluorescent protein (YFP) and Gaussia luciferase (GLuc) fusion protein
(YFP/GLuc). For in vivo phSPECT detection of this YFP/GLuc protein, a nanobody, targeted against yellow and
green fluorescent proteins (anti-YFP-Nb), was site specifically labelled with 99mTc.
Methods: Human embryonic kidney cells (HEK293T) were cultured and passaged every 3 days. 10E5 cells were
transduced with YFP/GLuc-containing vector: both membrane-targeted (MT-YFP/GLuc) and non-targeted (YFP/GLuc)
fusion proteins were developed. These vectors were compared against a SKOV-3 cell line stably expressing green
fluorescent-firefly luciferase (GFP/Fluc) and HEK293T cells expressing red fluorescent protein in combination with a
Gaussia luciferase (Red/GLuc). Transduction efficiencies were scored by fluorescence microscopy, and transduced cells
were enriched by fluorescence-activated cell sorting (FACS). GLuc and FLuc functionality was tested in vitro by
list-mode BLI. Subsequently, cells were transplanted subcutaneously in athymic (nu/nu) mice (MT-YFP/GLuc: n = 4,
YFP/GLuc: n = 6, GFP/FLuc: n = 6, Red/GLuc: n = 4). Labelling efficiency of anti-YFP-Nb was measured using instant
thin layer chromatography. One week after transplantation, 99mTc-labelled anti-YFP-Nb was injected intravenously
and pinhole (ph) SPECT/micro-CT was performed, followed by in vivo BLI.
Results: Cells showed high levels of fluorescence after transduction. The cells containing the MT-YFP/GLuc were
positive on fluorescence microscopy, with the fluorescent signal confined to the cell membrane. After cell sorting,
transduced cells were assayed by BLI and showed a significantly higher light output both in vitro and in vivo compared
with non-transduced HEK293T cells. The anti-YFP-Nb labelling efficiency was 98%, and subsequent phSPECT/micro-CT
demonstrated visible cell binding and significantly higher transplant-to-muscle ratio for both the MT-YFP/GLuc and
YFP/GLuc transplanted cells, compared with the GFP/FLuc and Red/GLuc group.
Conclusion: This study provides a proof of principle for a nanobody-based cell tracking method, using a YFP/GLuc
fusion protein and anti-YFP-Nb in a model of subcutaneously transplanted transduced HEK293T cells.
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A growing number of animal and preclinical studies reveal
the potential of cell-based therapies in a variety of applica-
tions [1], including myocardial infarction and beta-cell
precursor transplantation in diabetes. To evaluate the
long-term efficacy of these experimental treatments, it is* Correspondence: Lode.Goethals@vub.ac.be
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in any medium, provided the original work is puseful to monitor transplanted cells qualitatively and
quantitatively in vivo. Indirect cell labelling through re-
porter gene imaging provides an elegant method to per-
form such cell tracking [2]. Reporter genes are available
for different imaging modalities, which can be largely di-
vided into optical imaging, MRI and nuclear imaging
(PET/SPECT). Optical cell tracking exploits the sensitivity
of liquid-cooled CCD cameras with the inherently low
background signal to produce a high sensitivity (up to
10E − 17 mol/l) [3]. In contrast, luminescent signals are
difficult to quantify and suffer a high attenuation of visibles an Open Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
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parallel, nuclear imaging modalities generate a signal that
combines high sensitivity (up to 10E − 12 mol/l), with
quantitative 3D possibilities, when using adequate scatter
and attenuation corrections [3-5]. Commonly used SPECT-
or positron emission tomography (PET)-based reporter
gene systems include herpes simplex virus-thymidine kin-
ase (HSV-tk)-, sodium iodine symporter (NIS)- and mu-
tant dopamine receptor (D2R)-based systems [6-8].
This study investigates the feasibility of developing a
new multimodality cell tracking method, combining the
optical sensitivity and the quantitative possibilities of nu-
clear imaging with the advantageous physico-chemical
properties of nanobodies. Nanobodies are the antigen-
binding fragments from heavy-chain-only antibodies
naturally occurring in Camelidae [9]. Nanobodies are
considered to be the smallest intact antigen-binding
fragments derived from a functional antibody. Their lim-
ited size of approximately 15 kDa and their general ro-
bustness make them very suitable for in vivo imaging
[10]. Nanobodies labelled with 99mTc have been used for
targeting specific epitopes in vivo, for example, CEA and
EGFR2 [11,12].
In this study, we used an anti-green fluorescent pro-
tein (GFP) nanobody, labelled with 99mTc, to perform
in vivo cell tracking. This nanobody is cross-reactive
with both yellow fluorescent protein (YFP) and GFP, two
closely related fluorescent proteins [13,14]. As molecular
target, we transduced cells lentivirally with a fusion pro-
tein, consisting of a yellow fluorescent protein/Gaussia
luciferase (YFP/GLuc) fusion protein. This fusion protein
combines the fluorescence of YFP, a bright and versatile
fluorescent protein (excitation peak 514 nm, emission
peak 527 nm), with Gaussia luciferase, a naturally secretedFigure 1 Viral constructs encoding for the fusion proteins MT-YFP/GLluciferase, cloned from Gaussia princeps with coelentera-
zine as its substrate. The oxidation of coelenterazine does
not require ATP, and it is therefore also suitable for im-
aging when the protein is secreted or bound to the outer
cell membrane [15].
To facilitate recognition of the fluorescence epitope by
the nanobody, we generated a vector that displays the
YFP/GLuc fusion protein on its outer membrane [16]
and compared it against its intracellular counterpart.
Both were compared against a combined GFP/firefly lu-
ciferase (FLuc)-expressing cell line. Firefly luciferase has
been extensively utilized for in vivo bioluminescence and
catalyses the oxidation of D-luciferin to yield light with a
peak emission of 562 nm in the presence of O2, magne-
sium and ATP. Throughout this study, a red fluorescent
protein/Gaussia luciferase-expressing HEK293T cell line
(Red/GLuc) was used as a negative control.
In summary, the aim of this study was to provide a
proof of principle for the monitoring of transplanted




Lentiviral constructs were generated using standard mo-
lecular biology techniques (Figure 1). The YFP/GLuc fu-
sion protein was cloned into a lentiviral backbone (LV.
YFP/GLuc). The pDisplay™ vector (Life Technologies,
Invitrogen, Carlsbad, CA, USA), a vector that anchors
any protein to the cell membrane, was cloned into this
YFP/GLuc lentiviral backbone, yielding the LV.MT-YFP/
GLuc vector. A control vector was prepared by cloning
the GLuc gene into a lentiviral plasmid containing a red
fluorescent fluorochrome (Red/GLuc).uc (A), YFP/GLuc (B) and Red/GLuc (C).
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Human embryonic kidney (HEK) 293T cells were cultured
in Dulbecco's modified Eagle medium (DMEM), 10% fetal
bovine serum (FBS) and penicillin-streptomycin and pas-
saged every 3 days. Cells were grown at 37°C and in a 5%
CO2 atmosphere. A total of 100,000 cells were transduced
with all three of the aforementioned lentiviral vectors, and
2 days upon transduction, cells were sorted for fluores-
cence expression and subcloned cells were cultured ac-
cording to the above-mentioned protocol. A GFP and
firefly luciferase (FLuc)-expressing SKOV3 cell line was
purchased (Bio-Connect®, Huissen, the Netherlands).
Cell line validation in vitro: microscopy and in vitro BLI
Transduction efficiency was scored by fluorescence mi-
croscopy. Further localization of the fluorescent signal was
obtained by confocal microscopy (Zeiss LSM710 NLO
TiSa multiphoton confocal microscope using Zeiss
Zen2011 software, Carl Zeiss NV-SA, Zaventem, Belgium).
Luciferase functionality was determined using in vitro
bioluminescence imaging (BLI). HEK293T and SKOV3
cells were plated in six-well plates. For GLuc-expressing
cells, a coelenterazine solution (50 μl per well of a 1 mg/
ml solution) was added to approximately 2E6 cells per
well. In parallel, 2E6 FLuc-expressing SKOV3 cells were
imaged upon adding 150 μl of D-luciferin (30 mg/ml) per
well. Images were obtained with a Photo Imager camera
(Biospace, Paris, France) that allows list-mode acquisition.
Xenograft model
All animal experiments were performed with the ap-
proval of the ethical committee for animal research of
the Vrije Universiteit Brussel. During transplantation, all
mice were anaesthetized with a mixture of oxygen and
5% isoflurane and maintained with a mixture of oxygen
and 2.5% isoflurane. Twenty immune-deficient athymic
(nu/nu) mice were purchased (Charles River, Chatillon-
sur-Chalaronne, France). Cells growing exponentially in
culture were suspended in 150 μl of phosphate-buffered
saline (PBS) and 150 μl Matrigel (BD Biosciences, San
Jose, CA, USA) and transplanted subcutaneously in the
hind leg. Mice were inoculated with either MT-YFP/
GLuc-expressing cells (n = 4), YFP/GLuc-expressing cells
(n = 6) or cells that expressed Red/GLuc (n = 4). Also, six
mice were transplanted with the SKOV3 cells. All trans-
plants consisted of 2E6 cells.
In vivo BLI
BLI was performed immediately after SPECT/CT while
the animals were still anaesthetized. Coelenterazine
(1 mg/ml) or D-luciferin (30 mg/ml) was injected intra-
venously via the tail vein. A solution of 30 μl substrate and
120 μl NaCl was administered. Immediately after substrate
injection, mice were imaged using a Photo Imager camera(Biospace, France). Light emission was measured using
the large field-of-view setting and registered using the
photon counting technology during 1 min. A grey-scale
photographic image of the mice was fused with the bio-
luminescent images. The most intense luciferase signal is
shown in red, the weakest signal in blue. To analyse the
images, an elliptical region of interest (ROI) was drawn
over the transplant location, using a constant surface area.
Nanobody labelling
Nanobodies were labelled with 99mTc at their hexahisti-
dine tail. For the labelling, [99mTc(H2O)3(CO)3]
+ was syn-
thesized by adding 1 ml of 99mTcO4
− (0.84 to 3.7 GBq) to
an Isolink kit (Mallinckrodt Medical BV, Petten, the
Netherlands) containing 4.5 mg of sodium boranocarbo-
nate, 2.85 mg of sodium tetraborate, 10 mg H2O, 8.5 mg
of sodium tartrate and 7.15 mg of sodium carbonate at
pH 10.5. The vial was incubated at 100°C in a boiling bath
for 20 min. The freshly prepared [99mTc(H2O)3(CO)3]
+
was allowed to cool at room temperature for 5 min and
neutralized with 125 μl of 1 M HCl to pH 7 to 8. A total
of 500 μl of the tricarbonyl solution was added to 50 μl of
carbonate buffer at pH 8. The mixture was incubated
for 90 min at 60°C in a water bath. The 99mTc-nanobody
solution was purified on a NAP-5 column (GE Healthcare,
Little Chalfont, Buckinghamshire, UK) pre-equilibrated
with PBS. The labelling efficiency was determined by in-
stant thin layer chromatography.
Pinhole SPECT/micro-CT
One week after transplantation, anaesthesia was induced
with isoflurane gas 3% in an air/oxygen mixture. For the
induction of anaesthesia, ketamine/xylazine was given
intraperitoneally. The animal was placed in supine pos-
ition during acquisition, and images were acquired
60 min after tracer injection. Micro-CT imaging was
followed by pinhole SPECT on separate systems.
Micro-CT was performed using a dual-source CT
scanner (Skyscan 1178 micro-CT, Skyscan, Kontich,
Belgium) with a 60-kV voltage and 615-mA tube current
at a resolution of 83 μm. The total body scan time was
2 min. Images were reconstructed using filtered back
projection (NRecon; Skyscan).
The SPECT acquisitions were performed using a dual-
headed gamma camera (e.cam, Siemens Medical Solutions,
Hoffman Estates, IL, USA) equipped with a triple pinhole
collimator. The collimator has a focal length of 250 mm.
Sixty-four projections of each 30 s were acquired over 360°
of rotation into a 64 × 64 matrix. The total imaging time
was approximately 15 min.
To guide image fusion of the SPECT with the micro-CT,
two acrylic circular disks containing 3 3.7 MBq 57Co point
sources incorporated in organic ion exchange beads of 1-
mm diameter (Canberra, Zellik, Belgium) were firmly fixed
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eter and 3 mm in thickness. The six beads provided refer-
ence points in both imaging modalities and were used as
markers to generate a spatial transformation matrix. The
spatial position of the six fiducial markers was determined
manually using A Medical Image Data Examiner (AMIDE).
phSPECT images were analysed using AMIDE [17].
3D elliptical regions of interest were drawn around the
transplants on SPECT/micro-CT images. Transplant to
muscle ratios were calculated as the mean activity within
these ROIs divided by the mean activity within ROIs
drawn in muscle tissue.
In vitro biodistribution
After imaging, all animals were killed. Blood, liver, kid-
neys, muscle and transplants were dissected and weighed.
The amount of activity was determined using a gamma
counter (Canberra, Zellik, Belgium). Tracer uptake was
expressed as the percentage injected dose per gram of tis-
sue (%ID/g).
Statistical analysis
Average transplant-to-muscle ratios were compared be-
tween groups using the Kruskall-Wallis test. Post-hocFigure 2 Fluorescence microscopy of MT-YFP/GLuc (A), YFP/GLuc (B)comparisons were made by Mann-Whitney tests using a
Bonferroni correction for multiple testing.Results
Transduction efficiency
Fluorescence-activated cell sorting (FACS) showed a
positive fraction of 78% in the MT-YFP/GLuc group.
Within the YFP/GLuc group, 63% was positive. In the
Red/GLuc group, 62% was positive. These positive frac-
tions were sorted and subcultured.Cell line validation in vitro: microscopy and in vitro BLI
Functionality of the fluorescence in the in-house devel-
oped cell lines was shown using fluorescence microscopy
(Figure 2B,C). Confocal microscopy showed fluorescence
confined to the cell membrane in the MT-YFP/GLuc cell
line, suggesting proper targeting of protein to the cell
membrane (Figure 3A). In the YFP/GLuc cell line, the sig-
nal emanated from the cytoplasm as well as the cell mem-
brane and possibly even from the extracellular space.
In vitro BLI showed an increased light output in all
cell lines, compared with non-transduced HEK293T cells
(Figure 4A,B,C,D,E).and Red/GLuc (C) cell lines.
Figure 3 Confocal microscopy of MT-YFP/GLuc (A) and YFP/GLuc (B) cell lines, further localizing the fluorescent signal.
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In vivo BLI showed increased light output in all trans-
duced transplants compared with the non-transduced
transplant. This suggests viable transplants in every
transduced cell line (Figure 4A,B,C,D,E).
Nanobody labelling efficiency
Labelling efficiency of the anti-YFP nanobodies was in
excess of 98%.
Pinhole SPECT/micro-CT
A well-delineated spot of tracer accumulation was found
on the sites of inoculation in transplants in the MT-
YFP/GLuc and the YFP/GLuc groups, representing bind-
ing of the nanobody on the transplants. In the GFP/FLuc
and the Red/GLuc groups, no tracer uptake could be dis-
cerned within the transplants (Figure 5A,B,C,D). Image
processing yielded an average transplant-to-muscle ratio
of 0.85 ± 0.2 in the Red/GLuc group, 7.59 ± 1.34 in the
MT-YFP/GLuc group, 5.65 ± 0.8 in the YFP/GLuc group
and 1.1 ± 0.4 in the GFP/FLuc group. Kruskall-Wallis test-
ing showed a significance between groups. Post-hoc test-
ing using multiple Mann-Whitney tests further localizes
these differences between the YFP/GLuc and the GFP/
GLuc groups (p < 0.001) and between the GFP/GLuc and
the Red/GLuc (p < 0.001). Significance was also achieved
between the MT-YFP/GLuc group compared with the
Red/GLuc group (p < 0.001) and the GFP/GLuc group
(p < 0.001). No significance was noted between YFP/
GLuc and MT-YFP/GLuc, nor between the Red/GLuc
and GFP/FLuc.
In vitro biodistribution
Dissection results for the transplants, expressed as %ID/g,
are given in Table 1, confirming transplant targeting in theMT-YFP/GLuc and the YFP/GLuc groups, but not in the
Red/GLuc or the GFP/FLuc group.
Discussion
In this study, we developed a fusion protein, comprising
the yellow fluorescent protein (YFP), linked to Gaussia
luciferase (GLuc), as a molecular target for 99mTc-labelled
anti-YFP nanobodies.
To allow epitope recognition, we targeted this fusion
protein to the cell membrane using the pDisplay™ vector,
a 5.3-kb mammalian expression vector that allows dis-
play of proteins on the cell surface, using a fusion of the
protein at the N-terminus of the Ig κ chain leader se-
quence, which directs the protein to the secretory path-
way, and the C-terminus of the platelet-derived growth
factor receptor transmembrane domain, which anchors
the protein to the plasma membrane, displaying it on
the extracellular side [16].
The total size of this multimodal reporter system is ap-
proximately 50 kDa, leaving the expression cassette
small enough to be carried in most viral vectors [16].
Viral vectors encoding for two or even three pro-
teins, generated through recombinant DNA technol-
ogy, have been described, combining for example GFP
with thymidine kinase (TK) or FLuc with red fluores-
cent protein and TK, separated by an intra-ribosomal
entry site (IRES) sequence. These combinations yield
relatively long expression cassettes (up to 3.7 kb in
the case of FLuc-RFP-TK sequence) and suffer loss of
activity for the reporter downstream of the IRES
element [18]. To avoid this loss of activity, we used
the fusion protein YFP-GLuc rather than an IRES se-
quence separated vector. Fusion of proteins can lead
to inactivation of one or both parts of the fusion pro-
tein [18]. Throughout this study, the fusion of GLuc
Figure 4 In vitro and in vivo BLI. BLI was performed in the non-transduced HEK293T cell line (A), the MT-YFP/GLuc (B), YFP/GLuc (C), Red/GLuc
(D) and GFP/FLuc (E). All images are scaled to the same maximum.
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Localization of the fluorescent signal on confocal
microscopy showed a fluorescent signal confined to
the cell membrane in the MT-YFP/GLuc group. In the
non-targeted YFP/GLuc group, the fluorescent signal
was more heterogeneously distributed, as it originated
from the cytoplasm as well as from the cell mem-
brane and possibly even from the extracellular space.
The YFP/GLuc epitope was recognized in vivo by its
99mTc-anti-YFP nanobody in both the MT-YFP/GLucgroup and the YFP/GLuc group, with a higher transplant-
to-muscle ratio in the MT-YFP/GLuc group. A possible
explanation for these findings is found in the GLuc part
of the YFP/GLuc protein. Since GLuc DNA includes a
putative signal peptide sequence for secretion, GLuc nat-
urally enters the secretory pathway [19]. In the absence
of membrane anchorage, this might lead to portions of
the fusion protein on the membrane as well as intracel-
lularly and extracellularly. This hypothesis is strength-
ened by the lack of binding of the anti-YFP nanobody
onto the GFP/FLuc cell line since FLuc acts as an
Figure 5 Para-coronal SPECT/micro-CT fused images at the level of the transplants in the MT-YFP/GLuc (A), YFP/GLuc (B), Red/GLuc (C)
and GFP/Fluc (D).
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luciferin intracellularly [20].
This study is the first to exploit the advantageous
imaging properties of nanobodies for in vivo nuclear im-
aging in a context of reporter gene imaging, in combin-
ation with luminescence and fluorescence. Because of
these nanobody characteristics, especially the small size
(approximately 15 kDa), transplants are clearly distin-
guished on phSPECT/CT with average transplant-to-
muscle ratios of 7.59 as soon as 45 min after injection of
the tracer. Although comparison with other tracers is
difficult, Venisnik et al. achieved a similar %ID within
their transplants using an engineered anti-carcinoembryonic
antigen (CEA) antibody fused to a Gaussia luciferase. In our
study, we show a faster kinetics compared with Venisnik
et al. [21]. Undoubtedly, this faster in vivo kinetics owes to
the small size of the nanobody in comparison with a
Gaussia luciferase-engineered anti-CEA antibody [21].
During the past years, several reporter systems have
been developed that generate SPECT or PET contrast.
The most well known are the HSV-tk-, D2R- or NIS-
based systems. Each of these methods has its inherent
advantages and disadvantages. HSV-tk-based imaging
systems suffer high liver and intestinal background activ-
ity due to hepatobiliary excretion of tracers such as 18F-
FHPG [22]. The D2R-based
99mTc-TRODAT SPECT
system has a low dynamic range and yields only modest
signal to background activities due to the lipophilicity ofTable 1 Dissection data
Transplant (%ID/g) Muscle (%ID/g)
MT-YFP/GLuc 2.2 ± 0.9 0.2 ± 0.1
YFP/GLuc 1.8 ± 0.9 0.1 ± 0.1
Red/GLuc 0.2 ± 0,1 0.1 ± 0.1
GFP/FLuc 0.3 ± 0.2 0.2 ± 0.1
For MT-YFP/GLuc (n = 4), YFP/GLuc (n = 6), Red/GLuc (n = 4) and GFP/FLuc (n = 6) grthe tracer [23]. NIS-expressing transplants use 99mTc or
123I as tracer, with physiological uptake in the stomach,
thyroid and glandular tissue. Efflux of isotopes from the
cells due to lack of organification and low uptake of
tracers can compromise adequate cell tracking [24].
Intravenously injected radiolabelled nanobodies have a
specific biodistribution characterised by a high renal ex-
cretion, in combination with a low background signal in
other organs such as the liver, lungs and myocardium.
This allows high signal-to-noise ratios using this
nanobody-based imaging method for the long-term as-
sessment of cell therapy.
In the present study, the anti-YFP nanobody was la-
belled with 99mTc, but labelling of nanobodies with PET
radio-isotopes (18F or 68Ga) is feasible [25]. In addition,
labelling of antibody fragments with fluorescent labels as
well as MRI contrast is feasible [16], rendering this YFP-
anti-YFP reporter system applicable for multimodal in vivo
imaging studies.Conclusion
We provided proof of principle for a YFP-GLuc fusion
protein as reporter protein to perform noninvasive cell
tracking, in combination with a 99mTc-labelled anti-YFP
nanobody. Both the membrane-targeted and the non-
targeted lentiviral vector encoding for a YFP/GLuc fu-
sion protein could be targeted in vivo.Liver (%ID/g) Blood (%ID/g) Kidneys (%ID/g)
0.4 ± 0.2 0.2 ± 0.1 20.3 ± 7.3
0.4 ± 0.2 0.3 ± 0.1 20.4 ± 6.1
0.5 ± 0.2 03 ± 0.1 22.8 ± 6.2
0.4 ± 0.3 0.6 ± 0.2 30.2 ± 9.8
oups.
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